TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(U.S. dollars in millions, except for share data)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,319 | $3,226 |
| Accounts receivables, net of allowance for credit losses of $91 million and $95 million as of September 30, 2024 and December 31, 2023 | 3,462 | 3,408 |
| Inventories | 3,959 | 4,021 |
| Prepaid expenses | 1,127 | 1,255 |
| Other current assets | 445 | 504 |
| Assets held for sale | 2 | 70 |
| Total current assets | 12,314 | 12,485 |
| Deferred income taxes | 2,070 | 1,812 |
| Other non-current assets | 459 | 470 |
| Property, plant and equipment, net | 5,672 | 5,750 |
| Operating lease right-of-use assets, net | 364 | 397 |
| Identifiable intangible assets, net | 4,756 | 5,387 |
| Goodwill | 16,124 | 17,177 |
| Total assets | $41,758 | $43,479 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Short-term debt | $2,580 | $1,672 |
| Sales reserves and allowances | 3,785 | 3,535 |
| Accounts payables | 2,371 | 2,602 |
| Employee-related obligations | 619 | 611 |
| Accrued expenses | 2,984 | 2,771 |
| Other current liabilities | 1,241 | 1,044 |
| Liabilities held for sale | 216 | 13 |
| Total current liabilities | 13,797 | 12,247 |
| Long-term liabilities: | ||
| Deferred income taxes | 538 | 606 |
| Other taxes and long-term liabilities | 4,344 | 4,019 |
| Senior notes and loans | 16,400 | 18,161 |
| Operating lease liabilities | 295 | 320 |
| Total long-term liabilities | 21,578 | 23,106 |
| Total liabilities | 35,375 | 35,353 |
| Equity: | ||
| Teva shareholders’ equity: | ||
| Ordinary shares of NIS 0.10 par value per share; September 30, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively | 58 | 57 |
| Additional paid-in capital | 27,860 | 27,807 |
| Accumulated deficit | (14,956) | (13,534) |
| Accumulated other comprehensive loss | (2,769) | (2,697) |
| Treasury shares as of September 30, 2024 and December 31, 2023: 106 million ordinary shares | (4,128) | (4,128) |
| 6,065 | 7,506 | |
| Non-controlling interests | 319 | 620 |
| Total equity | 6,383 | 8,126 |
| Total liabilities and equity | $41,758 | $43,479 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.